João Cravo

João Cravo

Auto-generated profile, based on publicly available information

João Cravo

University of Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2026 in The Journal of Dermatology
Verified
Journal Article
Closed access
JCJoão Mendes Cravo
João Mendes Cravo
JVJoana Vieitez‐Frade
Joana Vieitez‐Frade
GAGustavo Almeida-Silva
Gustavo Almeida-Silva
MCMadalena Correia
Madalena Correia
CGCatarina Gregório
Catarina Gregório
JAJoana Antunes
Joana Antunes

28 August 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
DMDoralisa Morrone
Doralisa Morrone
MAMattia Alberti
Mattia Alberti
JCJoão Cravo
João Cravo
MPMaría Jesús Espinosa Pascual
María Jesús Espinosa Pascual
JMJoaquín Jesús Alonso Martín
Joaquín Jesús Alonso Martín
AAAna G. Almeida
Ana G. Almeida
Aims: Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a heterogeneous group of clinical entities requiring further investigation to assess aetiology. The European Society of Cardiology guidelines recommend advanced tests to establish an underlying mechanism. We evaluated advanced diagnostic testing utilization and real-world adherence to the current guideline in an international MINOCA registry. Methods and results: DOMINO is a prospective, multicentre, non-commercial registry enrolling 365 patients with MINOCA across 17 centres in 13 countries. Advanced testing was defined as cardiac magnetic resonance (CMR), intracoronary imaging, and/or invasive coronary functional assessment. The association between advanced testing and diagnostic resolution was assessed by multivariable logistic regression, with standard, cluster-robust, and generalized estimating equation (GEE) approaches to account for clustering by centre. Guideline-directed testing was performed in 254/365 (69.6%) and varied markedly by country (0–100%, P < 0.0001). A specific etiologic diagnosis was reached in 337/365 patients (92.3%). Advanced testing was associated with diagnostic resolution in the standard and GEE models, with a directionally consistent but non-significant cluster-robust estimate [standard odds ratio (OR) 3.94, 95% confidence interval (CI) 1.59–10.06; cluster-robust OR 3.75, 95% CI 0.95–14.72, P = 0.058; GEE OR 3.69, 95% CI 1.04–13.11]. Diagnostic resolution increased progressively with the extent of testing performed, from 85.6% with no advanced testing to 97.1% with CMR plus invasive/functional assessment (trend P = 0.02). Discharge pharmacotherapy varied significantly by etiologic diagnosis (P = 0.0001). Conclusion: Advanced diagnostic testing was associated with a higher likelihood of a determined etiologic diagnosis in MINOCA, despite marked international variability in its use; however, this association is partly definitional, as advanced testing directly contributes to diagnostic ascertainment for several etiologic categories. These findings nonetheless support closing the guideline-practice gap in advanced testing, while underscoring the need to distinguish mechanistically confirmed diagnoses from presumptive ones.

14 February 2025 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
JCJoão Cravo
João Cravo
JVJéssica Vasconcelos
Jéssica Vasconcelos
DPDiana Palácios
Diana Palácios
CSCatarina Sousa
Catarina Sousa
GSGlória Nunes da Silva
Glória Nunes da Silva

1 January 2025 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
DCDaniel Inácio Cazeiro
Daniel Inácio Cazeiro
JCJoão Cravo
João Cravo
MSMariana Pereira Silva
Mariana Pereira Silva
JIJoão R. Inácio
João R. Inácio
OMOana Moldovan
Oana Moldovan
RPRui Plácido
Rui Plácido
Discussão A HAP com envolvimento venoso/capilar (anteriormente denominada doença veno-oclusiva pulmonar [DVOP]/hemangiomatose capilar) é uma forma rara e grave de HAP, com incidência de 0,1 a 0,5 casos/milhão/ano. Essa condição compreende um processo fibroproliferativo dos compartimentos venosos e capilares pulmonares, com oclusão de pequenas veias causada por hipertrofia do músculo liso e deposição de colágeno. O diagnóstico de DVOP é desafiador devido à sua apresentação inespecífica, que muitas vezes mimetiza a HAP. Além disso, a confirmação histológica por biópsia pulmonar [...] Discussão A HAP com envolvimento venoso/capilar (anteriormente denominada doença veno-oclusiva pulmonar [DVOP]/hemangiomatose capilar) é uma forma rara e grave de HAP, com incidência de 0,1 a 0,5 casos/milhão/ano. Essa condição compreende um processo fibroproliferativo dos compartimentos venosos e capilares pulmonares, com oclusão de pequenas veias causada por hipertrofia do músculo liso e deposição de colágeno. O diagnóstico de DVOP é desafiador devido à sua apresentação inespecífica, que muitas vezes mimetiza a HAP. Além disso, a confirmação histológica por biópsia pulmonar

1 January 2025 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
DCDaniel Inácio Cazeiro
Daniel Inácio Cazeiro
JCJoão Cravo
João Cravo
MSMariana Pereira Silva
Mariana Pereira Silva
JIJoão R. Inácio
João R. Inácio
OMOana Moldovan
Oana Moldovan
RPRui Plácido
Rui Plácido
Discussion PAH with venous/capillary involvement (formerly referred to as pulmonary veno-occlusive disease [PVOD] /capillary hemangiomatosis) is a rare, severe form of PH, with an incidence of 0.1-0.5 cases/million/year. This condition comprises a fibroproliferative process of pulmonary venous and capillary compartments, with small vein occlusion caused by smooth muscle hypertrophy and collagen deposition. The diagnosis of PVOD is challenging due to its non-specific presentation, often mimicking PAH. Moreover, histological confirmation via lung biopsy is contraindicated due to the significant risk of [...] Discussion PAH with venous/capillary involvement (formerly referred to as pulmonary veno-occlusive disease [PVOD] /capillary hemangiomatosis) is a rare, severe form of PH, with an incidence of 0.1-0.5 cases/million/year. This condition comprises a fibroproliferative process of pulmonary venous and capillary compartments, with small vein occlusion caused by smooth muscle hypertrophy and collagen deposition. The diagnosis of PVOD is challenging due to its non-specific presentation, often mimicking PAH. Moreover, histological confirmation via lung biopsy is contraindicated due to the significant risk of